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Magnetically responsive layer-by-layer
microcapsules can be retained in cells and under
flow conditions to promote local drug release
without triggering ROS production†
Jordan E. Read, a Dong Luo, b Tina T. Chowdhury, c Rod J. Flower,a
Robin N. Poston, d Gleb B. Sukhorukov ‡c and David J. Gould *‡a
Nanoengineered vehicles have the potential to deliver cargo drugs directly to disease sites, but can
potentially be cleared by immune system cells or lymphatic drainage. In this study we explore the use of
magnetism to hold responsive particles at a delivery site, by incorporation of superparamagnetic iron
oxide nanoparticles (SPIONs) into layer-by-layer (LbL) microcapsules. Microcapsules with SPIONs were
rapidly phagocytosed by cells but did not trigger cellular ROS synthesis within 24 hours of delivery nor
affect cell viability. In a non-directional cell migration assay, SPION containing microcapsules signifi-
cantly inhibited movement of phagocytosing cells when placed in a magnetic field. Similarly, under flow
conditions, a magnetic field retained SPION containing microcapsules at a physiologic wall shear stress
of 0.751 dyne cm−2. Even when the SPION content was reduced to 20%, the majority of microcapsules
were still retained. Dexamethasone microcrystals were synthesised by solvent evaporation and under-
went LbL encapsulation with inclusion of a SPION layer. Despite a lower iron to volume content of
these structures compared to microcapsules, they were also retained under shear stress conditions and
displayed prolonged release of active drug, beyond 30 hours, measured using a glucocorticoid sensitive
reporter cell line generated in this study. Our observations suggest use of SPIONs for magnetic reten-
tion of LbL structures is both feasible and biocompatible and has potential application for improved
local drug delivery.
Introduction
Local treatment of disease is an important research goal
because it can potentially increase efficacy of drugs whilst
reducing side effects. To some extent this can be achieved by
direct delivery of therapeutics into disease sites which also pro-
motes local effects. However, with small molecule drugs and
biologics, we know that they can be rapidly cleared from joints
and other sites via the blood stream and lymphatics.1 An
alternative is to use nano or micron sized particles as drug car-
riers from which prolonged release can be achieved. However,
the persistence of vehicles at a desired site will depend on a
range of criteria including cell phagocytosis and degradation,
particle size, inflammation status of the site and lymphatic
drainage. Work by Horisawa et al., (2002) showed that nano-
sized PLGA particles are readily phagocytosed by macrophages,
whilst larger 26 µm particles remained extracellular in healthy
rat joints.2 When joints are inflamed, both nanosized
(300 nm) vehicles and larger micronsized particles are
removed by leakage and lymphatic drainage following intraar-
ticular delivery.3
Glucocorticoids have potent anti-inflammatory and analge-
sic effects and are widely used in the treatment of rheumatoid
and osteoarthritis patients by delivery directly to joints as
micronized crystalline suspensions that slowly dissolve and
have prolonged local effects.4 Nonetheless, following local
delivery burst release results in elevation in blood levels of
steroids5 which can cause systemic side effects.6 In addition
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there are reports of steroid crystals entering the lymphatics
and causing hypopigmentation of covering skin7–9 and injec-
tions can cause a flare in disease which results from ingestion
of crystals by phagocytic cells10,11 which can potentially
migrate away from the delivery site.
There are now a number of nanomedicines that are
approved for clinical use,12 generally they aim to promote drug
half-life or achieve a degree of passive targeting to disease
sites. Future developments in nanomedicine will be active tar-
geting to disease sites, triggered release in response to environ-
mental or physical cues13,14 and theranostic capacity.15 We are
interested nanoengineering delivery vehicles so that they are
better retained at disease sites and to improve local treatment
of disease. One nanoengineering approach, layer-by-layer (LbL)
assembly first described by Decher et al. (1992)16 is a simple
but flexible method to engineer nanoscale layers incorporating
responsive particles and biological molecules into complex
arrangements with functions ranging from sensors to drug
delivery.17–19 LbL assembly applied to microparticles was first
reported by Sukhorukov et al. (1998)20 by the sequential
addition of layers of alternatively charged polymers of approxi-
mately 2–3 nm in thickness21 on a template core. These micro-
capsules are ideally suited to the delivery of macromolecules
that can be trapped within the structure of the capsule
whereas small molecule drugs readily diffuse out unless they
have affinity for a capsule component,22 layers are crosslinked
to improve retention23 or high drug loading is achieved by use
of crystalline drug as the capsule core.24 One of their interest-
ing attributes is their potential for functionalisation through
incorporation nanocomponents which can permit responsive-
ness to physical stimuli. Inclusion of superparamagnetic iron
oxide nanoparticles (SPIONs) enables responsiveness to mag-
netism, which can be utilised to target vehicles25 and control
release of cargo molecules26 through the use of permanent
and alternating electromagnetic fields respectively. We know
that microcapsules are readily phagocytosed by cells27 and it is
feasible that magnetism could be used to retain microcapsules
at a delivered site and to prevent removal by cells or flow con-
ditions. Indeed a recent report has shown magnetic retention
of SPION containing microcapsules in the microvascular blood
supply.28 When SPIONs are used to provide magnetic respon-
siveness, there is however the concern that detrimental effects
on cells will be caused by the production of reactive oxygen
species (ROS).29 Iron is known to catalyse the Fenton reaction
that converts hydrogen peroxide, a product of lysosomes or
mitochondrial oxidative respiration, into a highly toxic
hydroxyl free radical (OH•). Despite this concern, in previous
studies we have shown that SPION containing microcapsules
are well tolerated by cells.25 In this study we demonstrate that
SPIONs incorporated into the microcapsule structure do not
promote ROS production in cells. We also demonstrate that
SPION containing microcapsules can be magnetically retained
in a cell migration assay and under flow conditions.
Furthermore, similar properties are seen with microcapsules
formed from crystals of the glucocorticoid dexamethasone
coated with polymer layers that incorporated SPIONs.
Experimental
Chemicals and reagents
All materials were supplied by Sigma-Aldrich unless otherwise
stated.
Fabrication of empty LbL microcapsules
Empty LbL microcapsules (Empty-LbL) were constructed on a
sacrificial calcium carbonate (CaCO3) template using the LbL
self-assembly technique (Fig. 1).30 In brief, 2.5 ml of 0.33 M
Calcium Chloride (CaCl2) and 2.5 ml of 0.33 M Sodium
Carbonate (Na2CO3) were combined in a beaker on a magnetic
stirrer at 800 RPM for 30 seconds, 400 RPM for 30 seconds,
then rested for 1 minute before centrifugation at 9000 RPM
and collection. Poly L-Arginine (PLA) and Dextran Sulphate
(DS) were used for biodegradable shells. All polymer solutions
were used at 2 mg mL−1 in 0.15 M Sodium Chloride (NaCl). Six
alternative layers, i.e. three of each polymer, were assembled in
total. PLA was assembled as the first layer by suspension of
cores and shaking at room temperature for 12 minutes.
Between polyelectrolyte layers, microcapsules were washed
twice in deionised water. For fluorescent visualisation PLA-
tetramethylrhodamine (PLA-TRITC) was added as the fifth
polyelectrolyte layer. For magnetic microcapsules (Empty-
LbL-Mag), SPIONs were synthesised as previously described31
then stabilised with citric acid and added in place of the
fourth layer, followed by addition of DS to adsorb any remain-
ing positive charge. For 100% SPION coverage stock nano-
particles in water of 45.8 µg ml−1 was used and this suspen-
sion was further diluted 1 : 2 and 1 : 5 when used for reduced
coverage.
Following multilayer assembly, the CaCO3 cores were dis-
solved in ethylenediametetraacetic acid (EDTA) solution.
Initially a 0.165 M solution of EDTA was added and micro-
capsules shaken for 7 minutes at room temperature. The con-
centration was increased to 0.2475 M and the shaking step
repeated. Finally, three 0.33 M EDTA washes were conducted
until cores were completely dissolved, when the microcapsules
were washed in deionised water and stored at 4 °C until use. A
summary of the structure of Empty-LbL and Empty-LbL-Mag
microcapsules is given in Table 1.
Fabrication of dexamethasone containing LbL microcapsules
Dexamethasone crystals were produced by dissolution of dexa-
methasone powder in acetone at a concentration of 10 mg
ml−1. 500 µL of dexamethasone–acetone solution was added to
2 mL of 2% Tween-80 in H2O and was sonicated using a
Piezon Master 400 dental sonication probe for 3 minutes at
maximum power. Dexamethasone solution was stir evaporated
at room temperature for 30 minutes, which formed crystals
which were collected via centrifugation at 9000 RPM for
2 minutes and then washed twice with deionised water. LbL
encapsulation of dexamethasone crystals (Dex-LbL) was carried
out immediately. Poly(allylamine hydrochloride) (PAH) and
poly(styrenesulfonate) (PSS) were used for synthetic shells.
These polymer solutions were again prepared at 2 mg mL−1 in
Paper Nanoscale
Nanoscale This journal is © The Royal Society of Chemistry 2020
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 2
5 
M
ar
ch
 2
02
0.
 D
ow
nl
oa
de
d 
on
 3
/2
5/
20
20
 2
:1
4:
44
 P
M
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
0.15 M NaCl. Eight polymer layers were assembled in total,
with PAH assembled as the first layer. For magnetic dexa-
methasone microcapsules (Dex-LbL-Mag), SPIONs were added
in place of the fourth layer followed by addition of PSS to neu-
tralise any remaining positive charge. A summary of the struc-
ture of Dex-LbL and Dex-LbL-Mag microcapsules is given in
Table 1.
Percentage encapsulation of dexamethasone was calculated
by application of layer washes to 293T.GRE.Luc+ cells at a
dilution of 1 : 100 in Dulbecco’s Modified Eagle Medium
(DMEM) cell culture media. For confirmation of stable
polymer layers, 20 μL of Dex-LbL microcapsules were spun
onto a glass slide, by centrifugation at 2000 RPM for
3 minutes. Dex-LbL crystals were viewed under phase contrast
and red fluorescence to image the drug crystal and PAH-TRITC
polyelectrolyte layer respectively, and images were overlaid. A
10 μL drop of acetonitrile was added to the structures to dis-
solve the dexamethasone and the field of view immediately
imaged again (Fig. S1†).
For all other steroid crystals, alterations were made to the
crystalisation method. For dissolution of prednisolone and
prednisolone acetate, chloroform :methanol (1 : 1) was used as
the solvent. Methylprednisolone acetate was dissolved in
acetone. Prednisolone crystals were then produced by the
above sonication method. Prednisolone acetate and methyl-
prednisolone acetate crystals required a homogenisation
method, in which 1 mL of steroid solution was added to 5 mL
of 2% Tween-80 in H20 and was homogenised using an IKA
Ultra Turrax T8 Homogenizer (Janke & Kunkel GmbH & Co.
KG) for 3 minutes at speed setting 4. Stir evaporation was
carried out as above and crystals were stored at 4 °C until use.
Scanning electron microscopy
Microcapsule and crystal appearance was assessed by imaging
using an FEI Inspect-F scanning electron microscope (SEM).
Following production, microcapsule samples were suspended
in 1 ml of deionised water before further dilution 1 : 10 in
deionised water. Three small drops were distributed on carbon
tape upon a metal stump and were allowed to dry completely.
For acetonitrile dissolution of LbL dexamethasone crystals,
10 μL of acetonitrile was subsequently added to stumps and
allowed to evaporate completely (Fig. S1†). Before imaging,
samples were sputter coated with gold using a Quorum
SC7620 sputter coater for 30 seconds. Coated samples were
imaged using the FEI inspect-F SEM with FEI xT microscope
control software, at varying magnifications up to 20 000×.
Generation of the enhanced green fluorescent protein (EGFP)
expressing HeLa cell line
For visualisation of cell movement, a HeLa cell line, stably
expressing EGFP was generated by transduction of HeLa cells
(ATCC® CCL-2™) with the EGFP encoding lentiviral construct
pHRSIN-CSGW-dlNotI (kindly provided by Dr Y. Ikeda, Mayo
Clinic, Rochester, MN). To produce lentivirus, 6.16 µg of
pHRSIN-CSGW-dlNotI construct was packaged via co-trans-
fection with, 1.5 µg pCMV-VSV-G, 6.13 µg pCMV-Δ8.2 and
68 µg polyethylenimine (PEI), into HEK 293T cells (ATCC®
CRL-3216™) seeded at 1 million per well in a 6-well plate. Cell
growth media was changed 5 hours post-transfection and cells
grown for 48 hours, before harvesting of virus containing
media. Media was applied to HeLa cells seeded at 10 000 per
well in a 6-well plate, with addition of 6 µg ml−1 polybrene to
the virus containing media. Cells were grown and monitored
for 48 hours, before transfer into a T25 tissue culture flask.
HeLa-EGFP cells were subjected to FACS sorting, to isolate and
Fig. 1 Production of polyelectrolyte layer-by-layer microcapsules. Shown is an overview of the production of LbL microcapsules. The process
begins with a core, upon which oppositely charged polyelectrolyte layers are added. The process ends with dissolution of the core (if sacrificial).
Cargo molecules can be encapsulated in the core, adsorbed in place of polyelectrolyte layers, or adsorbed to the microcapsule following core dis-
solution. A fluorescently labelled polyelectrolyte layer can be added for visualisation and a SPION layer can be added in place of a negatively
charged polyelectrolyte layer. The number of layers, polyelectrolytes used and biological molecule content can all be altered to tailor LbL micro-
capsules to the desired specifications.
Table 1 Structure of LbL microcapsules produced in this study. Shown
are the four types of microcapsules constructed and the order of poly-
electrolyte layers applied in their production
Microcapsule Composition of polyelectrolyte layers
Empty-LbL Sacrificial CaCO3 core/PLA/DS/PLA/DS/
PLA-TRITC/DS
Empty-LbL-Mag
(100%/50%/20%)
Sacrificial CaCO3 core/PLA/DS/PLA/
SPION/PLA-TRITC/DS
Dex-LbL Dex crystal/PAH/PSS/PAH/PSS/PAH/PSS/
PAH-TRITC/PSS
Dex-LbL-Mag Dex crystal/PAH/PSS/PAH/SPION/PAH/
PSS/PAH-TRITC/PSS
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subculture the 25% brightest EGFP expressing cells for use in
experiments.
Generation of the glucocorticoid responsive 293T.GRE.Luc+ cell
line
Oligonucleotides were designed that harbour the glucocorti-
coid responsive element (GRE, in bold), the sequence of the
forward primer was 5′ CTAGCACCTCACGGTACATTTTGTTCT-
GTGCCTCG 3′ and the reverse primer was 5′ CTAGCGAGGCAC-
AGAACAAAATGTACCGTGAGGTG 3′. These phosphorylated oli-
gonucleotides were annealed and repeats cloned between the
Nhe I and Xho I sites of the previously described plasmid
pCpGmCMVLuc+.32 Sequence analysis confirmed the con-
struction of a synthetic promoter consisting of 4 repeats of the
GRE upstream from the mCMV promoter. The expression cas-
sette was then transferred to the lentiviral vector LV.mCMV.
Luc+32 by PCR cloning, forming the vector pLV.GRE.Luc+.
Lentivirus was generated using the method described above
and virus containing media was applied to HEK 293T cells
seeded at 10 000 per well in a 6-well plate, with addition of
6 µg ml−1 polybrene to the virus containing media. Cells were
grown and monitored for 48 hours before transferring into a
T25 tissue culture flask. 293T.GRE.Luc+ cells were tested for
steroid responsiveness, using dilutions of dexamethasone.
Glucocorticoid responsiveness was monitored by measurement
of luciferase production. Cells were maintained in complete
media (Dulbecco’s Modified Eagle medium (DMEM, Gibco)
supplemented with 10% fetal calf serum (Gibco) 1% penicil-
lin–streptomycin and 1% L-glutamine). Cells were passaged
1 : 10, using trypsin EDTA, once a confluence of 100% was
reached and were used within 5 passages.
Confocal microscopy
To assess cell uptake of Empty-LbL-Mag microcapsules, HeLa
cells were plated on coverslips at a density of 10 000 per well in
a 6-well plate. 24 hours post plating, TRITC labelled Empty-
LbL-Mag microcapsules were added to the cells at a ratio of
10 : 1. Cells were incubated for 30 minutes, 1 hour and
2 hours. Cells were stained post treatment by washing twice in
ice cold PBS and subsequent addition of a 1× dilution of
CellMask™ Green Plasma Membrane Stain (ThermoFisher
Scientific) in cell culture media, for 10 minutes. To fix cells,
staining media was removed and 4% paraformaldehyde was
applied for 20 minutes at room temperature. Cells were washed
twice in PBS before mounting, using VECTASHIELD® mount-
ing media with 4′,6-diamidino-2-phenylindole (DAPI, Vector
Laboratories, Peterborough, UK). Cells were immediately
imaged using an LSM 880 confocal microscope with Airyscan
(Zeiss Microscopy, Cambridge, UK) and Zen 2.3 software
(Zeiss), using the DAPI, 488 nm and 568 nm laser channels
and a 40× objective. All image analysis and processing was
carried out using Zen 2.3 Lite software (Zeiss).
Cell migration assay
HeLa-EGFP cells were seeded at a density of 20 000 cells per
well in 6-well plates in a central circle, defined using parafilm
cut with a 6 mm biopsy punch. On the underside of the well a
grid was drawn with fluorescent marker, as shown in Fig. 3A.
After 6 hours incubation at 37 °C cells had attached and media
was replaced with fresh complete media. Microcapsules were
applied at a 1 : 1 ratio to the plated cells and incubated for
24 hours. At time point 0 hours the parafilm was removed,
cells washed twice with complete media and fresh 2 ml of
media applied to each well. Circular 5 mm diameter × 5 mm
thick N42 Neodymium Magnets (Magnet Expert Ltd,
Nottinghamshire, UK) were used, which had maximum field
strength of 191 mT as measured with a HT201 gaussmeter
(EMF, UK). Magnets were applied to the underside of relevant
wells directly below the circle of cells and remained in place
for the duration of the experiment, aside from imaging. Areas
of interest adjoining to the central circle (Fig. 3A) were imaged
at 0, 96, 120, 144 and 168 hours using an EVOS™ digital
colour fluorescence microscope (Thermo Fisher Scientific UK)
in the four defined areas of interest, under the DAPI and EGFP
fluorescence channels.
The DAPI and EGFP images were overlaid into a composite
image. Image analysis was performed with a macro written in
Image Pro software. Thresholds were set for the EGFP colour
channel so that the cells but not the background were
detected. No measurements were carried out with the DAPI as
it was used only for the purpose of lining up the images on the
microscope for imaging. For EGFP, the area of interest was
selected as the whole field of view and the data recorded for
the % area filled with EGFP, corresponding to the area filled
with cells.
ROS assay
293T.GRE.Luc+ and HeLa cells plated at a density of 20 000
cells in 96-well plates were treated for 2 hours or 24 hours with
defined numbers of microcapsules or equivalent concen-
trations of SPIONs, diluted in DMEM supplemented with 5%
FCS, 1% pen–strep and 1% L-glutamine, before ROS assays
were carried out. Treatments were removed and cells washed
once with warmed DMEM. 100 µL of dichloro-dihydro-fluor-
escein diacetate (DCFH-DA, Sigma-Aldrich), diluted in serum
free DMEM to a concentration of 10 µM was added to wells
and incubated in the dark at 37 °C for 30 minutes.
Plate fluorescence was read at excitation/emission 485 nm/
535 nm using a Tecan GENios microplate reader (Tecan Group
Ltd, Männedorf, Switzerland). For additional stimulation of
ROS, 100 µL of 0.01% hydrogen peroxide, diluted in DMEM
media was added following removal of media. Cells were incu-
bated at 37 °C for 1 hour, before washing and detection of ROS
with DCFH-DA.
Cell viability
In parallel with the ROS experiments, cells that were similarly
treated with microcapsules or SPIONs were assessed for cell
viability after 24 hours of treatment. In these experiments the
CellTiter-Glo® (Promega Corp) assay was performed by
addition of 100 μl titreGLO assay reagent to each well. Plates
were briefly shaken and then incubated for 20 minutes before
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the luminescent signal in 1 second was recorded using a plate
luminometer.
Ferene-S iron assays
Ferene-S assay was carried out using the method described by
Hedayati et al., (2018).33 Iron standards between 0 and 100 µg
were produced using the TraceCERT® Iron Standard for ICP.
Defined numbers of microcapsules or SPIONs, suspended in
100 µL PBS were dissolved by mixing with 100 µL concen-
trated nitric acid and incubated for 2 hours at 80 °C. Acid was
neutralised by addition of 160 µL 10 N sodium hydroxide.
Ferene-S Assay working solution was prepared, composition
0.2 M L-ascorbic acid, 0.4 M acetate buffer, 0.1 M Ferene-S.
900 µL of Ferene-S Assay working solution was added to
100 µL of iron standard, microcapsule or nanoparticle
sample and incubated at room temperature for 30 minutes.
Absorbance of 300 µL of samples was read in triplicate in a
96-well plate, at 595 nm, using a MultiSkan FC (Thermo
Fisher Scientific UK). Iron concentrations were determined
using the standard curve and nanoparticle and microcapsule
iron content calculated.
Flow system investigations
As a model for therapeutic microcapsules immobilised by a
magnet, a flow system was assembled using an Econo-
Column® peristaltic pump (Bio-Rad Laboratories Ltd,
Hertfordshire, UK). Initial collections of volumes of deionised
H20 over a period of 1 minute at each flow speed were con-
ducted to determine flow rate in µl min−1. The terminal length
of plastic tubing was applied across a 0.9 kg pull rectangular
10 × 3.5 × 2.25 mm thick N45 neodymium magnet with a
maximum field strength of 182.5 mT at the poles. To test
retention of magnetic microcapsules, 5 million microcapsules
were applied to the flow system by reverse pumping at low
speed until they reached the magnet. Flow was reverted to the
forward direction and the slowest pump speed selected. After
5 minutes at each flow speed, photographs were taken and the
retention of the microcapsules assessed by densitometry ana-
lysis of the photographs, using ImageJ (https://imagej.nih.gov/
ij/index.html).
Measurement of dexamethasone release from magnetically
retained microcapsules
10 million LbL-Dex or LbL-Dex-mag microcapsules were applied
to the flow system by reverse pumping at low speed until they
reached the magnet. Flow was reverted to the forward direction
at flow speed 5 (0.385 dyne cm−2). Flow through of deionised
water containing released dexamethasone was collected every
20 minutes for 10 hours then at 24, 30 and 48 hours. At termin-
ation of the experiment the magnet was removed from the
tubing and the remaining deionised water in the system col-
lected, with any remaining microcapsules. To assay dexametha-
sone, 293T.GRE.Luc+ cells were plated at a seeding density of
20 000 cells per well in a 96 well plate. Samples from the flow
experiment were applied to cells in triplicate at a 1 : 5 dilution
in DMEM supplemented with 5% FCS, 1% pen–strep and 1%
L-glutamine. 24 hours post-treatment cells were lysed with
passive lysis buffer (50 μl). A luciferase assay was performed on
lysates (10 μl) in white plastic 96-well plates to which 50 μl of
assay reagent was automatically added using an MLX
Microtiter® Plate Luminometer (Dynex Technologies Inc.,
Chantilly, VA, USA) and light emission measured for 10
seconds. Dexamethasone standard concentrations were applied
to the cells to produce a standard curve.
Statistical methods
Statistical analysis of results was carried out using GraphPad
Prism 7.04 (GraphPad Software, La Jolla California, USA). For
analysis of flow retention experiments, results were subjected
to 2-way ANOVA analysis with multiple comparisons and post-
hoc Bonferroni test. For cell retention experiments, results
were subjected to 2-way ANOVA analysis with multiple com-
parisons (simple effect within rows) and post-hoc Turkey test.
ROS assay data was subjected to one-way ANOVA with multiple
comparisons and Fisher’s LSD post-hoc test.
Results and discussion
LbL microcapsules have many features that make them suited
to application in drug delivery.34,35 They can be assembled from
FDA approved polymers under native conditions which are com-
patible with a range of bioactive molecules from DNA and pro-
teins through to small molecule drugs. Beyond this, micro-
capsules can be loaded with particles that provide responsive-
ness to physical signals such as gold nanoparticles for NIR laser
heating36 and SPIONs for magnetic responsiveness. We are par-
ticularly interested in magnetic responsiveness as we have pre-
viously shown targeted delivery25 and controlled release through
this attribute.26 In the present study, we have turned our atten-
tion to magnetic retention which could be important when
microcapsules are delivered to a disease site and the aim is to
prevent their removal in order to promote local drug effects.
Microcapsule appearance and cell uptake
Empty non-magnetic (Empty-LbL) and magnetic micro-
capsules (Empty-LbL-Mag) were characterised using SEM,
fluorescent and confocal microscopy. Microcapsules were
measured as 2.57 ± 0.10 µm in diameter (Fig. 2A). The SPION
layer was visible as a roughened surface in Empty-LbL-Mag.
Both types of microcapsule were of similar size and resemble
those reported in previous studies made by the LbL sacrificial
calcium carbonate core method.25,37 Fluorescence microscopy
confirmed a TRITC labelled PLA layer, with a hollow microcap-
sule core (Fig. 2B), which enabled confocal microscopy visual-
isation of microcapsule interaction with HeLa cells. Time-
course incubation of SPION containing microcapsules with
HeLa cells demonstrated interaction after just 30 minutes,
maintained through 2 hours of co-incubation (Fig. 2C). In
addition, Z-stack confocal scanning indicated that after 1 hour
of incubation, microcapsules were inside the cells. Many of
the microcapsules were adjacent to the nucleus which again is
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consistent with previous observations of standard micro-
capsules in other cells.38 Importantly, there are no obvious
differences in the appearance of cells, microcapsule uptake
rate or intracellular trafficking when the magnetic version are
delivered.
Controlling SPION content of microcapsules correlates with
measurement of iron content
To date, studies utilising magnetic microcapsules have typi-
cally used an excess of SPIONs to produce one or more com-
plete iron oxide shells.25,39,40 Here, to establish more stringent
control over the iron content of the microcapsules, empty core
magnetic microcapsules were made with varying percentage
coverage of SPIONs in the fourth layer. Visual analysis of
microcapsules assembled with 100%, 50% and 20% SPION
suspension clearly demonstrated that as the nanoparticle
content was reduced, the roughened surface appearance of the
microcapsules was reduced accordingly (Fig. 3A). Using the
Ferene-S assay (standard curve Fig. 3B) the iron content of
microcapsules with 100% SPION coverage was measured to be
20.2 pg per microcapsule (Fig. 3C). Dilution of SPION suspen-
sion 1 : 2 produced microcapsules with a lower iron content of
12.28 pg per microcapsule (Fig. 3C), about 60% of the iron
content of the microcapsules prepared with the 100% suspen-
sion. A further dilution of the SPIONs to 1 in 5 produced
microcapsules with an iron content of 4.11 pg per microcap-
sule, and 20.3% of the iron content of the microcapsules pre-
pared with the 100% suspension (Fig. 3C). The ability to alter
SPION content could ensure the minimum iron content to
achieve a desired functional effect, whilst increasing microcap-
sule biocompatibility could potentially permit delivery of
higher microcapsule doses or facilitate repeat delivery. Our
data would suggest that there is further scope to reduce SPION
content of microcapsules whilst retaining magnetic respon-
siveness. What the precise lower limit of SPION content is will
largely depend on the magnetic function that is required.
Biocompatibility of microcapsules containing SPIONs and
their influence on ROS production
Iron is a catalyst of free radical production including the toxic
OH• from H2O2 which can cause cell death. In view of this,
there are concerns that iron nanoparticles can lead to ROS pro-
duction. We have previously observed that SPION containing
microcapsules do not alter cell viability except when they are at
high ratios to cells and after prolonged exposure.25 Here we
saw that SPION containing microcapsules did not alter the via-
bility of HeLa or 293T cells after 24 hours of exposure (Fig. 3D)
and furthermore there was no induction of ROS regardless of
the iron content of microcapsules, compared to control
untreated cells (Fig. 3E). Similarly, delivery of free magnetite
nanoparticles, equivalent to the content in microcapsules, also
had no effect on cell viability (Fig. 2D) or ROS production
(Fig. 3E). Our observations are in agreement with other
researchers. Könczöl et al., (2011)41 showed that A549 cells
exposed to a similar concentration (10 µg ml−1) of slightly
Fig. 2 Image analysis of layer-by-layer microcapsules. (A) representative SEM images of a control empty core LbL microcapsule (Empty-LbL) (left)
and an LbL microcapsule with SPION layer (Empty-LbL-Mag) (right) magnification 80 000×. (B) Representative fluorescent image of the PLA-TRITC
layer of a control Empty-LbL microcapsule. (C) Time course confocal microscopy of interaction of Empty-LbL-Mag microcapsules (red) with HeLa
cells (green) and their DAPI stained nuclei (blue).
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larger (20–60 nm) magnetite nanoparticles for 24 hours had
ROS levels comparable to control cells. Whilst, Aranda et al.
(2013)42 incubated smaller magnetite nanoparticles (8 nm)
with primary rat hepatocytes and saw no increase in ROS pro-
duction until cells were exposed to an Fe3O4 concentration of
50 µg ml−1 for 24 hours. Although our results clearly show that
the levels of ROS produced by cells after delivery of micro-
capsules containing SPIONs are not elevated it has been
reported that similar citrate coated small magnetite nano-
particles can induce a transient increase in cellular stress
which was evident by an increase of malonyldialdehyde (an
indicator of lipid peroxidation) immediately after delivery to a
macrophage cell line.43 We examined ROS production 2 hours
after delivery of microcapsules or nanoparticles to cells but
again there was no change in this parameter from untreated
cells (Fig. S2†). Concentration of iron is clearly an important
factor. The observations on cellular stress made by Stroh used
magnetite in excess of 300 µg ml−1 and the effects observed on
ROS production seen by Aranda followed use of 50 µg ml−1
whereas the concentration delivered in our microcapsule study
equates to a maximum of 4 µg ml−1. Further work exploring
the kinetics of cell utilisation of the iron delivered in micro-
capsules will be useful when repeat delivery is considered in
order to avoid accumulation of iron to levels that alter cell
function and viability.
Another possibility to be considered is that SPIONs will
exacerbate hydroxyl radical (OH•) synthesis if they are delivered
into an environment containing H2O2. If we consider the use
of SPION containing microcapsules in treatment of inflamma-
tory conditions this is important because H2O2 released from
activated polymorphonuclear leucocytes can be present in the
inflammatory milieu. ESI (Fig. S3A†) shows that hydrogen per-
oxide treatment (1 hour) of cells causes a dose dependent
increase in ROS production. When cells were pre-treated
(24 hours) with free SPIONs or SPION containing micro-
capsules before exposure to a suboptimal concentration of
H2O2 (0.01%) for an hour there was no further exacerbation of
ROS production (Fig. S3B†). These observations are encoura-
ging for the in vivo use of SPION containing microcapsules in
inflammatory environments.
Retention of cells following delivery of SPION containing
microcapsules
Magnetic microcapsules may be of use in maintaining encap-
sulated drugs in their desired area of action within the body.
One issue to overcome is the possibility that phagocytic cells
may engulf microcapsules and remove them from the site of
action. To this end, cell retention studies were carried out to
determine whether the iron content of the Empty-LbL-Mag
microcapsules was sufficient to prevent cell movement in a
magnetic field. In this assay a magnet was placed directly
beneath the cells which generated the magnetic field (strength
maximum of 200 mT in the centre) illustrated in Fig. S4.†
Images were collected at set time points after the start of the
experiment (Fig. 4A and B) and these were used to determine
the movement of HeLa-EGFP cells into adjacent areas of inter-
Fig. 3 Production of reactive oxygen species in response to SPION con-
taining microcapsules. (A) Appearance of Empty-LbL-Mag microcapsules
made with dilutions of SPION suspensions, using Scanning Electron
Microscopy. (B) Ferene-S iron assay standard curve used to determine iron
content of microcapsules. (C) Table showing the iron content of SPION
containing Empty-LbL-Mag microcapsules in terms pg iron per microcap-
sule, content in 20000 microcapsules as added to experimental wells for
a 1 : 1 ratio of microcapsules: cells, and as a μg mL−1 concentration. (D)
Viability of 293T.GRE.Luc+ cells or HeLa cells treated with a 1 : 1 ratio of
Empty-LbL-Mag microcapsules: cells, or the equivalent number of free
SPIONS for 24 hours as determined using CellTiter viability assay. (E)
Production of ROS in 293T.GRE.Luc+ cells or HeLa cells treated with a 1 : 1
ratio of Empty-LbL-Mag microcapsules: cells, or the equivalent number of
free SPIONS for 24 hours. As a control Empty-LbL microcapsules with no
SPIONs were added at 1 : 1 ratio of microcapsules: cells. N = 3. Standard
error of the mean in bar charts is shown by the vertical lines.
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est by image analysis. HeLa-EGFP cells containing Empty-
LbL-Mag microcapsules at a 1 : 1 ratio of microcapsules to
cells, moved significantly less than control cells at all time
points beyond 96 hours when they were placed in a magnetic
field. At 120 hours cells preincubated with Empty-LbL-Mag
microcapsules in a magnetic field (Fig. 4B and C:- 1 : 1 mag +
magnet) had filled 4.29% of the area of interest, demonstrating
significantly less movement than control cells (22.12%, p =
0.0316), control cells in a magnetic field (control mag, 24.49%,
p = 0.009), cells + Empty-LbL (1 : 1 non-mag, 22.63%, p =
0.0244) and cells + Empty-LbL microcapsules in a magnetic
field (1 : 1 non-mag + magnet, 21.26%, p = 0.0477). At
144 hours, cells preincubated with Empty-LbL-Mag micro-
capsules and exposed to a magnetic field had filled 8.38% of
the area of interest, significantly less than all other cell treat-
ments (p = 0.035). This observation was maintained through
to 168 hours, where cells with Empty-LbL-Mag microcapsules
in a magnetic field had filled only 10.53% of the region of
interest (p = 0.0023); significantly less compared to all other
cell treatments (Fig. 4C). The observations in this experiment
are important for several reasons; firstly, because they further
support the idea that SPION containing microcapsules are
inert in cells, because in the absence of a magnetic field they
did not significantly alter cell migration in this assay, even at
the longest timepoint. When cells containing SPION contain-
ing microcapsules (Empty-LbL-Mag) were placed in a fixed
magnetic field, the distance they migrated was dramatically
inhibited. This inhibition was solely due to the interaction of
the SPION containing microcapsules with the magnetic field,
as movement of HeLa cells containing standard microcapsules
Fig. 4 Retention of HeLa-EGFP cells treated with SPION containing microcapsules (Empty-LbL-Mag) in a magnetic field. (A) Schematic of experi-
mental set up. Green circle represents area of plated HeLa-EGFP cells, grey circle represents 5 mm neodymium magnet, blue lines represent refer-
ence grid and the rectangles represent the four areas of interest imaged, one border of which is adjacent to the area of plating as shown. The
magnified region shows a representation of an imaged area of interest, with migrated cells. (B) HeLa-EGFP cell images taken in a single area of inter-
est over the time course of a single experiment. (C) Movement of HeLa-EGFP cells treated with control Empty-LbL microcapsules (Empty mcs) or
SPION containing Empty-LbL-Mag microcapsules (Magnetic mcs (100% SPION shell)) into the area of interest, under control conditions or when
subjected to a magnetic field from a N42 neodymium magnet. Area of interest values are the mean of four separate areas of interest and error bars
represent standard error of the mean. Cell movement into the areas of interest was measured at intervals up to 168 hours. Significant differences are
indicated by *p < 0.05, **p < 0.01. #p < 0.05 relative to all other treatments at the same timepoint. Data is representative of two experimental
repeats.
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(Empty-LbL) was not inhibited. These results are encouraging
and suggest that it may be possible to retain microcapsules
engulfed by cells at a delivered site in vivo if similar interaction
with a magnetic field can be recapitulated.
Retention of microcapsules with different SPION contents in a
flow system
Application of SPION containing Empty-LbL-Mag micro-
capsules to a flow system demonstrated that even micro-
capsules prepared with a 20% SPION suspension were retained
at shear stresses between 0.046–0.751 dyne cm−2 (corres-
ponding to flow speeds between 0.1–1.64 ml min−1 in a
1.5 mm diameter tube) (Fig. 5). Densitometry analysis of
microcapsule pellets retained on a fixed magnet demonstrated
that as the shear stress increased, there was no loss in reten-
tion of the 100% SPION shell microcapsules until the highest
stress of 0.751 dyne cm−2 was reached (Fig. 5B), where a 10%
reduction was observed. For the microcapsules prepared with
50% and 20% SPION suspensions retention was reduced to
90% and 85% respectively by a shear stress of 0.385 dyne cm−2
and was further reduced to 80% retention for both shell con-
tents at the highest shear stress (Fig. 5). These observations
with a flow system (shear rates of 0.046–0.751 dyne cm−2) show
that SPION containing microcapsules could potentially be
magnetically retained in the type of flow and shear stress con-
ditions observed in lymphatic vessels (2 µl per hour44 to 30 µl
min−1 45) and have average shear stress of 0.64 dyne cm−2.46
Although flow rates increase during inflammation to reduce
oedema and facilitate removal of cells.47 Based on our find-
ings, retention may also be possible in small veins (diameters
from 800 µm to 1.8 mm) where flow rates of 1.2–4.8 ml min−1
have been measured, corresponding to shear stresses of
between 0.028–3.435 dyne cm−2.48
Generation of steroid crystals coated with LbL assemblies
Multiple steroids are used in the treatment of inflammatory
conditions; hence we used four steroids for formulation into
solvent evaporation steroid crystals. Dexamethasone crystals
had a homogenous appearance and were approximately 9.22 ±
0.68 µm in size, with a rounded, flattened cuboidal shape of
depth 1.49 ± 0.11 µm (Fig. 6A). Prednisolone crystals had less
homogeneity, with crystals mostly hexagonal in shape and
with an average size of 4.32 ± 0.42 µm, depth 0.82 ± 0.12 µm.
Prednisolone acetate formulated as crystals gave a hom-
ogenous suspension of triangular shape crystals, with an
average size of 5.44 ± 0.13 µm and depth 0.29 ± 0.04 µm.
Methylprednisolone crystals were long and octagonal in shape
with an average length of 8.89 ± 0.43 µm, width of 2.71 ±
0.16 µm and depth of 0.37 ± 0.03 µm (Fig. 6A). In comparison
to crystalline steroid preparations currently used clinically to
treat inflammation in arthritic joints, such as Depo-Medrol®,
our crystals were more homogenous in size and shape, have a
smoother surface and are of similar size.49
To confirm stable polymer layers, LbL encapsulated dexa-
methasone crystals were imaged using fluorescence
microscopy and scanning electron microscopy, before and
after dissolution with acetonitrile (ESI Fig. S1†). Prior to dis-
solution the dexamethasone crystals and fluorescent polyelec-
trolyte layer were both clearly visible (Fig. S1A–C†). After dis-
solution with acetonitrile, the dexamethasone crystals were no
longer visible, but the fluorescent polyelectrolyte layer was still
visible and intact, confirming that the polyelectrolyte layers
formed a stable structure around the steroid crystal (Fig. S1D–
F†). SEM imaging was used to confirm these findings, also
showing that following acetonitrile dissolution, the polyelec-
trolyte shells remained visible and retained the crystal shape,
whilst the solid crystal was no longer visible (Fig. S1G and H†).
Fig. 5 Retention of magnetic microcapsules in a flow system. (A) Images of retained Empty-LbL-Mag microcapsules in 1.5 mm diameter tubing,
taken using a fixed position camera following 5 minutes at each flow speed. In the absence of microcapsules no band was seen, and (B) quantified %
retention of Empty-LbL-Mag microcapsules in a flow system at increasing shear stresses for 5 minutes per condition (expressed as a % of retention
compared to the value at the lowest shear stress of 0.046 dyne cm−2).
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The LbL method used within this paper is well characterised
and has been used many times before on both colloidal sacrifi-
cial cores and crystalline cores.24,25
When a layer of SPIONs was included in the coating of dexa-
methasone crystals (Dex-LbL-Mag), they were a largely hom-
ogenous suspension of flattened cuboidal crystals of size 9.22
± 0.68 µm, with slightly rounded square sides and with a dexa-
methasone encapsulation efficiency calculated to be up to
99.99%. The iron content was measured to be approximately
5.03 pg per microcapsule and the distribution of SPIONs was
largely on the narrow edge of the crystals as shown (Fig. 6B).
The reason for this distribution around the narrow edge of the
crystals may be because this surface has an increased charge,
due to its curvature and rough layer growth at the edge, in
comparison to the flat face of the crystals, therefore the
SPIONs attach more readily on this surface. Alternatively, the
SPIONs may attach to the planar crystal surfaces but many are
mechanically sheared off when the planar surfaces slide across
each other in the shaking stages of the encapsulation process.
Responsiveness of 293T.GRE.Luc+ cells
In order to monitor dexamethasone release from fabricated
microcapsules, the glucocorticoid responsive cell line, 293T.
GRE.Luc+ was used. Treatment of the 293T.GRE.Luc+ cell line
with dexamethasone standard concentrations between 0.1 nM
and 10 µM demonstrated that the cells were sensitive between
1 nM and 10 µM, as shown by a near-linear dose response
(Fig. 7A). Treatment of 293T.GRE.Luc+ cells with a 1 : 1 ratio of
un-encapsulated dexamethasone crystals, Dex-LbL and Dex-
LbL-Mag demonstrated dexamethasone release from all struc-
tures, resulting in significant luciferase production compared
to untreated cells after 24 hours. Luciferase production was
increased 109.2-fold over control levels in cells treated with
Dex crystals (7624.3 ± 440.8 vs. 69.8 ± 1.3, p < 0.0001). Dex-LbL
microcapsules drove luciferase production 129.3-fold over
control levels (9024.1 ± 759.9 p < 0.0001) and Dex-LbL-Mag
microcapsules drove luciferase production 102.5-fold over
control levels (7154.0 ± 693.4, p < 0.0001) (Fig. 7B). Biological
activity was also shown for all the different steroid crystals by
treatment of GC responsive 293T cells (data not shown). Most
studies that monitor steroid release from vehicles use HPLC or
UV-Vis absorbance to quantitate steroid release. HPLC has a
reported limit of quantification around 10 nM50,51 and UV/Vis
has a lower detection limit of around 1 µM.52,53 The reporter
cell line we generated utilising an optimally designed promo-
ter for low basal activity and robust activation32 enabled us to
accurately measure dexamethasone concentrations in the
range 1 nM to 10 µM. In addition to improved sensitivity, the
reporter cells also have the advantage that it confirms biologi-
cal activity of the drug. This type of transcriptionally respon-
sive system is particularly useful in monitoring drug released
from nano/micro fabricated vehicles and can be combined
with imaging modalities to monitor positional effects of
released drug.25
When we coated our dexamethasone crystals with polymer
layers their appearance was not altered and they released
similar amounts of dexamethasone as uncoated crystals.
When dexamethasone has previously been coated in LbL
layers, irregular micronized crystals of the drug have been
used.54,55 Pargaonkar et al., (2005)54 sonicated crystals in the
presence of poly(diallyldimethylammonium chloride) (PDDA)
to form nanosized crystals (mean diameter 420 nm) which
they coated in different polymer layers, whilst Stewart et al.55
generated LbL structures similar in size (7.40 µm) to the ones
we constructed. In both studies rapid release (100% within
120 minutes) of dexamethasone from LbL structures was
Fig. 6 Crystals of different corticosteroids. (A) SEM images of different corticosteroid crystals made by the oil-in-water emulsion technique. (B) SEM
of LbL encapsulated dexamethasone crystals with a SPION layer (Dex-LbL-Mag).
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Fig. 7 Dexamethasone response of 293T.GRE.Luc+: (A) luciferase response of 293T.GRE.Luc+ cells to standard concentrations of dexamethasone
solution after 24 hours. (B) Luciferase response of 293T.GRE.Luc+ cells to dexamethasone crystal constructs applied at a 1 : 1 ratio of crystals to cells
after 24 hours. Each value is the mean of triplicate readings and error bars are standard error of the mean; **** represents a significant difference of
p < 0.0001 compared to control cell response.
Fig. 8 Retention of magnetic LbL encapsulated dexamethasone crystals in a flow system. (A) Images of retained dexamethasone crystals in a flow
tube, which are quantified in the bar chart below. Dexamethasone crystals in a flow system when subjected to increasing shear stress for 5 minutes
at each shear stress rate (expressed as a % of retention at lowest shear stress of 0.046 dyne cm−2). (B) Luciferase response of 293T-GRE-Luc+ cells
to dexamethasone released into deionised water from non-magnetic dexamethasone crystals (Dex-LbL) or SPION containing LbL dexamethasone
crystals (Dex-LbL-Mag) retained in the tubing with a permanent magnet over a period of 24 hours. ***p < 0.001 (compared to time matched Dex-LbL).
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observed, but Pargaonkar et al. (2005)54 observed a slower rate
of release with increasing number of microcapsule polymer
layers. Prednisolone crystals have also been incorporated into
LbL structures56 and again slower release was observed when
coated with more polymer layers.
Prolonged release of Dex from crystals magnetically retained
in a flow system
In order to determine whether prolonged dexamethasone
release in a flow system was possible, densitometry analysis was
carried out on pellets of SPION containing Dex-LbL-Mag micro-
capsules applied to a fixed magnet in the flow system of increas-
ing shear stress. Retention of Dex-LbL-Mag at the lowest stress
of 0.046 dyne cm−2 was 100%, reducing to 95.36% at 0.385 dyne
cm−2 and further reducing to 90.57% at the highest stress of
0.751 dyne cm−2 (Fig. 8A). Long term retention studies carried
out at the lowest shear stress of 0.046 dyne cm−2 over a
48 hours period demonstrated that dexamethasone was
removed from the flow system after 4 hours of application when
non-magnetic Dex-LbL microcapsules were applied to the fixed
magnet (Fig. 8B). Application of SPION containing Dex-
LbL-Mag microcapsules demonstrated a significantly longer
release of dexamethasone over a period of 48 hours.
Quantification of dexamethasone in the flow through was sig-
nificantly higher for Dex-LbL-Mag at 2 hours post application,
with luciferase response measuring 3962.7 ± 150.0 RLU com-
pared to 7.79 ± 3.60 RLU for Dex-LbL (p < 0.001). The concen-
tration of dexamethasone in the flow through remained signifi-
cantly higher for Dex-LbL-Mag (3600.13 ± 399.60 RLU Luc) com-
pared to baseline values for Dex-LbL until 8 hours post appli-
cation (p < 0.001). Beyond this time point, samples for Dex-LbL
were not collected. Between 8 hours and 48 hours the concen-
tration of dexamethasone in the flow through from Dex-
LbL-Mag microcapsules steadily declined but even after
48 hours the dexamethasone level was above 5 nM.
Furthermore, the remaining water collected from the flow
system after 48 hours also contained measurable dexametha-
sone so the Dex-LbL-Mag microcapsules were still not exhausted
at the end of this experiment. Clearly these studies show that
magnetically retained Dex-LbL-Mag microcapsules result in pro-
longed release of dexamethasone under shear stress conditions
beyond 30 hours. Whilst this compares favourably to the rapid
release seen from dexamethasone LbL structures in other
reports54,55 direct comparison is not possible due to differences
in the protocols of the release experiments. Taken together the
data suggests that these dexamethasone microcapsules could
potentially be magnetically retained at a delivered site, achieve
prolonged drug action and resist removal by flow forces either
in the lymphatics or small blood vessels.
Conclusions
Our experiments show that SPION containing microcapsules do
not cause cellular stress following delivery and they can be mag-
netically retained at sites under both physiologically relevant
shear stress conditions and following cell engulfment. A
summary of the main findings of this study can be found in
Table 2. If we can demonstrate the same characteristics in vivo
we should be able to retain vehicles at delivery sites in order to
promote local drug effects. We show how this approach can be
utilised with magnetically responsive dexamethasone crystals
and anticipate that it could be explored with other drug cargoes.
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